PaxMedica
Update in progressPXMD (OTC Markets OTCPK)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
PaxMedica, Inc. is a clinical-stage biopharmaceutical company developing anti-purinergic therapies for neuro-related disorders. Its lead candidate, PAX-101 (intravenous suramin), is in Phase 3 for autism spectrum disorder and other conditions. PAX-102 is an intranasal suramin candidate; PAX-HAT-301 targets HAT. A PolarMar Health collaboration covers emodin for ASD. Formerly Purinix, founded 2018, based in Tarrytown, NY.
Company score
- Sentiment
- 0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!